Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1Carcinoma, Ovarian Epithelial 1

Interventions

Dexamethasone 116daratumumab 68Lenalidomide 67Bortezomib 55pomalidomide 45carfilzomib 40Cyclophosphamide 33Calcium Dobesilate 32Specimen Handling 30Biopsy 28Magnetic Resonance Spectroscopy 25isatuximab 20belantamab mafodotin 20talquetamab 17iberdomide 17fludarabine 17Melphalan 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 14fludarabine phosphate 11selinexor 10elotuzumab 10tocilizumab 9X-Rays 8Nivolumab 8trametinib 7Sirolimus 7Whole-Body Irradiation 6Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × Clarithromycin × 90 days × Clear all
NCT04302324 2026-05-20

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
11 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡